Novel Approaches to Diagnose COVID-19

Abstract = 382 times | PDF = 125 times

Main Article Content

Solaf Jawhar Ali

Abstract

An widespread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 has occurred worldwide.  Public health agencies are in need of developing diagnostic tools which will have a major impact in tracking the virus and suppressing the transmission. Diagnosis of the disease is based on clinical symptoms, epidemiological history and laboratory examinations. Severe acute respiratory diseases with fever and ,cough and dyspnea, are used as the case definition to select people for testing. Different samples taken from the human body such as oropharyngeal (OP) and nasopharyngeal (NP) swabs are used to detect the virus. SARS-CoV-2 can be detected with different methods in the laboratory including real time RT-PCR, chest CT scan and immunoassays. Viral nucleic acid testing has played important role in control COVIDI-19 outbreak.  More recently, a new CRISPR-based DETECTR assay has been developed to detect COVID-19. This test is rapid (~30 min), low-cost, and precise for identification of SARS-CoV-2. In addition, immunoassays and medical imaging can use as supplementary tests, combined with RT-PCR. This review is conducted to summarizes the current information on the present diagnostic approaches for SARS-CoV-2.

Keywords

COVID-19

Downloads

Download data is not yet available.

Article Details

References

[1] L. Zhang, F. M. Shen, F. Chen, and Z. Lin, “Origin and evolution of the 2019 novel coronavirus,” Clin. Infect. Dis., no. Ml, pp. 2019–2020, 2020.
[2] Q. Bi et al., “Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study,” Lancet Infect. Dis., vol. 3099, no. 20, pp. 1–9, 2020.
[3] G. Kolifarhood et al., “19; a Narrative Review,” Clin. Asp. COVID, vol. 8, no. 1, p. 41, 2020.
[4] S. S. Unhale, Q. B. Ansar, S. Sanap, S. Thakhre, and S. Wadatkar, “a Review on Corona Virus ( Covid-19 ),” World J. Pharm. Life Sci., vol. 6, no. 4, pp. 109–115, 2020.
[5] P. Vetter, D. L. Vu, A. G. L’Huillier, M. Schibler, L. Kaiser, and F. Jacquerioz, “Clinical features of covid-19,” BMJ, vol. 369, no. April, pp. 1–2, 2020.
[6] R. Li et al., “Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2),” Science, vol. 3221, no. January, pp. 1–8, 2020.
[7] Y. W. Tang, J. E. Schmitz, D. H. Persing, and C. W. Stratton, “The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges,” J. Clin. Microbiol., no. April, pp. 1–22, 2020.
[8] R. Lu et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” Lancet, vol. 395, no. 10224, pp. 565–574, 2020.
[9] M. L. Holshue et al., “First case of 2019 novel coronavirus in the United States,” N. Engl. J. Med., vol. 382, no. 10, pp. 929–936, 2020.
[10] R. Konrad et al., “Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020,” Eurosurveillance, vol. 25, no. 9, pp. 2–6, 2020.
[11] I.-C. A. Alcoba-Florez JGonzalez-Montelongo R, “Fast SARS-CoV-2 detection protocol based on RNA precipitation and RT-qPCR in nasopharyngeal swab samples,” pp. 1–22, 2020.
[12] B. G. S. Hilaire et al., “A rapid, low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing,” bioRxiv, p. 2020.04.25.061499, 2020.
[13] J. P. Broughton et al., “CRISPR – Cas12-based detection of SARS-CoV-2,” 2019.
[14] Y. Li and L. Xia, “Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management,” AJR. Am. J. Roentgenol., no. June, pp. 1–7, 2020, doi: 10.2214/AJR.20.22954.
[15] D. Dong et al., “The role of imaging in the detection and management of COVID - 19 : a review,” 2020,
[16] Y. Yang et al., “Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections,” medRxiv, p. 2020.02.11.20021493, 2020.
[17] W. Liu et al., “Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2,” J. Clin. Microbiol., no. March, 2020.
[18] Z. Li et al., “Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis,” J. Med. Virol., no. February, 2020.
[19] B. Diao et al., “Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein,” medRxiv, p. 2020.03.07.20032524, 2020.
[20] M. J. Loeffelholz and Y. W. Tang, “Laboratory diagnosis of emerging human coronavirus infections–the state of the art,” Emerg. Microbes Infect., vol. 9, no. 1, pp. 747–756, 2020.
[21] V. C. Bachelet, “Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature,” Medwave, vol. 20, no. 03, pp. e7891–e7891, 2020.